A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 15, 2026 - P2 | N=23 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Dec 2029 ➔ Apr 2032
Trial completion date • CNS Disorders • Multiple Sclerosis
|